title: Improving follow-up rates in spontaneous adverse drug reaction reporting: effectiveness of a targeted letter used by a regional centre in the UK.
abstract: BACKGROUND
  Spontaneous reports of suspected adverse drug reactions to regulatory bodies and market authorization holders are important in pharmacovigilance. Follow-up information, which can be difficult to obtain, is often required from reporters; therefore, we developed targeted follow-up letters that we hoped would make replying easier.
  
  
  OBJECTIVE
  To examine the effects of introducing targeted letters on responses to follow-up requests from a regional pharmacovigilance centre in the UK.
  
  
  METHODS
  In January 2001 we redesigned our follow-up request letter to include tick-boxes targeted to obtain the appropriate information from reporters. Response rates and the requirement for a second follow-up letter were examined for the 5-year period before introduction of the targeted follow-up letter (1996-2000) and the 5 years after the change to the targeted follow-up system (2001-5). In an 18-month sub-study examining data from 2001-2, time from the production of the first targeted follow-up letter to receipt of a response from reporters was also measured.
  
  
  RESULTS
  The introduction of targeted follow-up letters was associated with an increase in the mean annual response rate for follow-up from 36.4% in the 5 years pre-targeted follow-up to 60.5% in the 5 years post-targeted follow-up (p < 0.0001). Fifty percent of all successful follow-up responses were obtained within 70 days.
  
  
  CONCLUSIONS
  Targeted follow-up letters were associated with increased follow-up success rates. Results also indicate that closing cases to follow-up information at 70 days would allow collection of 78% of all follow-up that would ever arrive.
authors.affiliation: West Midlands Centre for Adverse Drug Reactions, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
authors.forename: Christopher
authors.initials: C
authors.lastname: Anton
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Cox
authors.forename: Robin E
authors.initials: RE
authors.lastname: Ferner
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D005500:Follow-Up Studies; D006801:Humans; D006113:United Kingdom